EpiCast Report: Uveitis - Epidemiology Forecast to 2026
Uveitis is the inflammation of the uveal tract (iris, ciliary body, and choroid), but can also cause the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. Anatomically, uveitis is classified by the main site of inflammation as anterior, intermediate, posterior, and panuveitis. Anterior uveitis is the most common form, is localized to the anterior chamber of the eye, and includes iritis, iridocyclitis, and anterior cylitis. Uveitis can occur in an acute, recurrent, or chronic manner.
This analysis provides detailed, granular, and clinically-relevant segmentations of uveitis cases. This analysis is further strengthened by its adherence to the standard clinical guidelines provided by the IUSG and SUN. By using the same guidelines across the different markets, GlobalData epidemiologists were able to conduct meaningful comparisons and analyses of the forecast results.
In the 7MM, the diagnosed incident cases of uveitis will increase from 402,343 cases in 2016 to 420,627 cases in 2026, at an Annual Growth Rate (AGR) of 0.45% per year. GlobalData forecasts that all markets except Germany and Japan will see an increase in the diagnosed incident cases of uveitis during the forecast period. In 2016, there were 992,827 diagnosed prevalent cases of uveitis in the 7MM, which is expected to increase to 1,115,226 cases by 2026, at an AGR of 1.23%. Among the 7MM, the US had the highest number of diagnosed prevalent cases of uveitis in 2016 and 2026, at 361,513 cases and 414,835 cases, respectively.
- The Uveitis EpiCast Report provides an overview of the risk factors and global trends of uveitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It also includes a 10-year epidemiology forecast of the diagnosed incident and diagnosed prevalent cases of uveitis in these markets from 2016-2026. The diagnosed incident and prevalent cases are further segmented by sex and age (starting at age 0 years up to ages 80 years and older) and by anatomical site of inflammation (anterior, intermediate, posterior, and panuveitis). The diagnosed incident cases are also segmented by course of disease (acute, chronic, and recurrent).
- The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Uveitis EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global uveitis market.
- Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for uveitis therapeutics in each of the markets covered.
- Understand magnitude of uveitis population by course of disease and anatomical site of inflammation.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Uveitis: Executive Summary 4
2.1 Related Reports 7
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 10
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 14
3.4 Forecast Methodology 15
3.4.1 Sources 16
3.4.2 Forecast Assumptions and Methods 21
3.5 Epidemiological Forecast for Uveitis (2016-2026) 29
3.5.1 Diagnosed Incident Cases of Uveitis 29
3.5.2 Diagnosed Prevalent Cases of Uveitis 30
3.5.3 Age-Specific Diagnosed Prevalent Cases of Uveitis 31
3.5.4 Sex-Specific Diagnosed Prevalent Cases of Uveitis 32
3.5.5 Diagnosed Prevalent Cases by Anatomical Site of Inflammation 33
3.5.6 Diagnosed Prevalent Cases by Etiology 34
3.6 Discussion 35
3.6.1 Epidemiological Forecast Insight 35
3.6.2 Limitations of the Analysis 36
3.6.3 Strengths of the Analysis 37
4 Appendix 38
4.1 Bibliography 38
4.2 About the Authors 41
4.2.1 Epidemiologist 41
4.2.2 Reviewers 41
4.2.3 Global Director of Therapy Analysis and Epidemiology 42
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 42
4.3 About GlobalData 43
4.4 Contact Us 43
4.5 Disclaimer 43
1.1 List of Tables
Table 1: Risk Factors, Comorbidities, and Associated Diseases for Uveitis 9
Table 2: 7MM, Diagnosed Incident Cases of Uveitis, Both Sexes, All Ages, N, Select Years, 2016-2026 30
Table 3: 7MM, Diagnosed Prevalent Cases of Uveitis, Both Sexes, All Ages, N, Select Years, 2016-2026 31
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of Uveitis, Both Sexes, All Ages, N, 2016 and 2026 5
Figure 2: 7MM, Diagnosed Prevalent Cases of Uveitis, Both Sexes, All Ages, N, 2016 and 2026 6
Figure 3: Age-Standardized Diagnosed Prevalence of Uveitis, Men, All Ages, 2006-2026 11
Figure 4: Age-Standardized Diagnosed Prevalence of Uveitis, Women, All Ages, 2006-2026 12
Figure 5: Case Flow Map for Diagnosed Incident and Prevalent Cases of Uveitis 15
Figure 6: Sources Used for Diagnosed Incidence 16
Figure 7: Sources Used for Diagnosed Incident Cases by Anatomical Location of Inflammation 17
Figure 8: Sources Used for Diagnosed Incident Cases by Course of Disease 18
Figure 9: Sources Used for Diagnosed Incident Cases by Severity 19
Figure 10: Sources Used and Not Used for Diagnosed Prevalence 20
Figure 11: Sources Used for Diagnosed Prevalent Cases by Anatomical Location of Inflammation 21
Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of Uveitis, Both Sexes, N, 2016 32
Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of Uveitis, All Ages, N, 2016 33
Figure 14: 7MM, Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Both Sexes, All Ages, N, 2016 34
Figure 15: 7MM, Diagnosed Prevalent Cases of Uveitis by Etiology, Both Sexes, All Ages, N, 2016 35
Make an enquiry before buying this Report
Please fill the enquiry form below.